SARS-CoV-2 proteome microarray for COVID-19 patient sera profiling

The immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteome is largely unknown. Here we describe a protocol for analyzing sera samples with SARS-CoV-2 proteome microarray. The proteins were expressed by either E. coli expression system or eukaryotic cell expression sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Dan-yun, Jiang, He-wei, Li, Yang, Zhang, Hai-nan, Tao, Sheng-ce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882418/
https://www.ncbi.nlm.nih.gov/pubmed/35310073
http://dx.doi.org/10.1016/j.xpro.2022.101238
Descripción
Sumario:The immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteome is largely unknown. Here we describe a protocol for analyzing sera samples with SARS-CoV-2 proteome microarray. The proteins were expressed by either E. coli expression system or eukaryotic cell expression systems and obtained by affinity purification. The protocol includes microarray fabricating and sera profiling, which will be used to build an antibody response landscape for IgG and IgM. The protocol may help to facilitate a deeper understanding of immunity related to SARS-CoV-2. For complete details on the use and execution of this protocol, please refer to Li et al. (2021c).

Ejemplares similares